Allogene Therapeutics Inc (NASDAQ:ALLO) shares, rose in value on Wednesday, February 12, with the stock price up by 2.14% to the previous day’s close as strong demand from buyers drove the stock to $1.43.
Actively observing the price movement in the last trading, the stock closed the session at $1.40, falling within a range of $1.32 and $1.46. The value of beta (5-year monthly) was 0.836. Referring to stock’s 52-week performance, its high was $5.78, and the low was $1.36. On the whole, ALLO has fluctuated by -26.67% over the past month.
With the market capitalization of Allogene Therapeutics Inc currently standing at about $299.83 million, investors are eagerly awaiting this quarter’s results, scheduled for in March.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 10.5k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ALLO’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of ALLO currently trading nearly -18.00% and -27.66% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 28.60, while the 7-day volatility ratio is showing 7.45% which for the 30-day chart, stands at 7.98%. Furthermore, Allogene Therapeutics Inc (ALLO)’s beta value is 1.06, and its average true range (ATR) is 0.14.
A comparison of Allogene Therapeutics Inc (ALLO) with its peers suggests the former has fared considerably weaker in the market. ALLO showed an intraday change of 2.14% in last session, and over the past year, it shrunk by -67.35%%.
Data on historical trading for Allogene Therapeutics Inc (NASDAQ:ALLO) indicates that the trading volumes over the past 10 days have averaged 2.77 and over the past 3 months, they’ve averaged 2.71 million. According to company’s latest data on outstanding shares, there are 209.50 million shares outstanding.
Nearly 32.84% of Allogene Therapeutics Inc’s shares belong to company insiders and institutional investors own 68.05% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 32.05 million shares as on 2025-01-31, resulting in a short ratio of 11.7. According to the data, the short interest in Allogene Therapeutics Inc (ALLO) stood at 2149.00 of shares outstanding as of 2025-01-31; the number of short shares registered in 2024-12-31 reached 30.91 million. The stock has fallen by -32.86% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ALLO stock heading into the next quarter.
